Clinical Trial Update: Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring [Phase 1, Phase 2]

View source ↗

Summary

NRG Oncology completed a Phase 1/2 trial evaluating Niraparib added to standard hormone and radiation therapy for high-risk prostate cancer; results were posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Niraparib (Zejula) (Niraparib)

Snippet

Sponsor: NRG Oncology | Conditions: Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8 | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-07-11